Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.

Americans are paying more than $900 a month for popular weight-loss drugs Ozempic and Wegovy, but drugmakers want to sell generic versions of the drugs for less than $100. That is according to ...

Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the US government’s Medicare program ...

Sept 17 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations ...

In June, Jorgensen agreed to testify over the pricing of Ozempic in the U.S., as well as that of the drugmaker's hugely popular weight loss drug Wegovy. Sanders, who chairs the Senate committee ...

(Reuters) - Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations, Bloomberg News reported on Tuesday ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP-1 medicines like Ozempic can help stop that. In a new decades-long ...

Share on Pinterest Four key factors can greatly impact how much weight people lose while taking GLP-1 drugs like Ozempic, Wegovy, Victoza, and Saxenda. Daniel Llao Calvet/Getty Images Researchers ...

In a sweeping new lawsuit, over 900 people are claiming that Ozempic and other GLP-1 drugs caused them gastrointestinal injuries, sometimes even after ceasing use of them. "If the hazard is ...

Dolores Catania is ready for her next dose of Ozempic — stat. “I am taking my shot tomorrow,” the “Real Housewives of New Jersey” star exclusively told Page Six Wednesday night at the ...

Kourtney Kardashian is expanding her wellness empire with a new product alternative to GLP-1 medications like Ozempic. Here's why it might be a bad idea Kourtney Kardashian Barker has recently ...